Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
8, I'll take that rating, better than the dufus from Opco Leland dirtbag!
8, Piper Sandler analyst Yasmeen Rahimi has a very impressive bio she was with Roth Capital.
8, Thanks, maybe we'll see an uptick tomorrow at opening???
Attn:
There's something going on in AMRN stock is trading after hours around 7ish????
gold, that's the approx shs outstanding it's not the float. It's complicated. If I was inclined I could break down the float but it's not worth the effort.
gold, Goldman is the lead underwriter the other firms listed to the right and left of the lead underwriter are participants in the order of how many shares they take down in the offering. Actually, the more firms on the cover of the prospectus the better, since it provides a better distribution of the shares thus placing shares in weak and/or strong hands. There's so much wheeling and dealing when the book is handled by a giant firm like Goldman you wouldn't believe it, they're not angles!! If it's a hot deal there's always payback when the next hot deal comes along.
gold, your rational is skewed, price of a stock doesn't always reflect the strength or weakness of their financial statement. It's the fundamentals of supply and demand. In the case of AMRN the supply far outweighs the demand. When volume starts increasing keep an eye out for news regardless of whether it's good or negative.
gold, as of June 30, 2019 Amrn had cash of $221 mill before the secondary. On July 19, 2019 they filed the form 425 raised approx $420 mill after commissions. They needed the proceeds to build out vascepa. In hindsight it's a good thing they raised that money, fast forward if they didn't raise the $420 the shareholders would be SOL as of today!!!
Gold, you can't compare oranges to apples. OSTK was a different set of circumstances. AMRN's secondary was discounted due to risk. Goldman and the other underwriters screwed the existing shareholders. Why do you think that everytime the stock makes a move the shorts are all over it. There are too many shs out in the float. The only way to get rid of the shorts in AMRN is a BO.
BB, Oh yeah I recall the games that were played with OSTK. First problem is the lack of the uptick rule which the SEC did away with yrs ago, then to get back at the shorts OSTK "issued shares" but were tightly held so weren't in the public float. Stock loan depts within the prime brokers are the most profitable but no one talks about it, the harder the stock is to borrow the higher interest rates the prime brokers charge the hedgies or whoever is trying to borrow the shares. It's complicated.
Agreed on all fronts. Du has laid the groundwork for her political career. It's not what you know, it's who you know. Works every time.
HK, I'm technically challenged, thanks for sharing your talents. Much better!
Isaeed, BB
NO I didn't know that!!! lol What you say BB???
interesting tweet, Matthew Natale
https://twitter.com/MatthewTNatale/status/1298005948003475460?s=20
jas, thanks for posting link.
BB, besides a cure for HIV, Gild made billions with their cure for Hep C. I believe that's why Gild will be successful with the NASH trial. Gild is a victim of their own success, they need Vascepa to keep them relevant. Plus, they're now sitting on a ton of cash.
Marjac, eleven days till D day. Will someone post the link with instructions so we can listen to the OA?
Raf, I'll find out and put her name out there, why not? At this juncture, it can only help, love conspiracy theories!
sts, Miraxion-for Parkinson
sts, my reference to fish oil was intended to be sarcastic.
jas, maybe meow is aka steve giordino!!! lol
MNbio, read Concapk's post#273300, it's very informative and revealing how the law clerk, Peggy Vannozzi, wound up writing the 3/30 decision.
It makes so much sense when you read it.
Raf...Yes, Yes and Yes
it doesn't mean they can't pursue other applications for the drug, as did Amarin. Of course it would be years in the making. In the meantime Amarin still has vascepa and the EU approval, I hope!!!! That's assuming we lose the appeal.
ILT, I agree 100%. Epeleuton being a synthetic drug won't be laughed at by Adam Fartstein or MRC and all the other naysayers of "fish oil". Yes, give the docs a cheaper version of vascepa and of course they will write off label scripts all day long. I truly believe Amarin needs Epeleuton in its portfolio. The synergies are there.
Your research is probably accurate. I sense something is in the works.
ILT.
As you mentioned in past. It's too coincidental and incessant to not be connected to epeleuton. Especially w same investors.
It would be a tremendous addition to amarin pipeline.
Raf, Thanks, we're on our way!
HK, your humility is apparent from your writings, very refreshing. You have my utmost respect. Thank you for all you do.
cardio, do you walk on water too? I hope you have a ton of medical malpractice ins. Aren't you required to partake in CME's? It's docs like you who give the profession a bad rap.
Part 2
article from an Irish publication
ALTHOUGH Amarin, formerly known as Ethical Holdings, is headquartered in London, its roots are largely Irish.
A number of former Elan executives work in the company which is chaired by former Elan finance director Tom Lynch.
From the early days it attracted the attention of a number of high profile Irish investors including Dermot Desmond, Tony Ryan and John Climax.
The current chief executive Rick Stewart was asked to join the company by Tom Lynch when he was still at an Elan competitor.
Amarin also has collaborations for its development programmes with a number of universities including Trinity College.
Outside of Miraxion, Amarin's core development pipeline also includes the global rights to an oral formulation of apomorphine for treating patients with advanced Parkinson's Disease.
AILISH O'HORA
I decided to devote some time today to do some serious DD on the background of Amarin Pharma aka Ethical Holdings. Holy Cow, there's some serious history of this company that will blow the minds of the many shareholders who post on this forum. At the risk of sounding naive and I apologize if the original posters on the board know the background of Amarin, BUT there's definitely a connection between the original cast of characters from the Ethical Holding aka Amarin and DS Biopharma/Afimmunne/epeleuton. Major original investors in Ethical Holdings were Drs. Dermot Desmond, Tony Ryan and guess who.. Dr. John Climax. If you're so inclined google the previous 3 names and their affiliations. Mind-boggling megabucks financiers. Fast forward check out the recent research findings of the epeleuton trial along with Dr. Bhatt etal. Also, as an added FYI, (approx. 2013) Amarin sold their soul to Biopharma Secured Investment Holdings, Caymon LP aka CPPIB for a $100million investment in return Amarin had the privilege of repaying them $150million. That loan agreement was tied to any future sale of the company and the rights to Vascepa. Fortunately for us as of August 2020 there will be only $10mill outstanding.
https://www.irishtimes.com/business/health-pharma/amarin-an-overnight-success-10-years-in-the-making-1.3651730#.XzgtsIwbiBI.mailto
ILT,
Because Afimmune is competition it doesn't mean that Amarin couldn't swoop them up and tuck them into a subsidiary. It happened in the taser patent deal that Du referred to in the May article written in the Nevada law review mag when she mentioned that she was being tutored on technical issues such as how taser work and the benefits of fish oil. It happened that Taser Intl was bought out by Axon because they lost the patent lawsuit and Axon said the hell with them and just went ahead and bought Taser Intl.
Same could happen with Amarin and Afimmune. The synergies are there and Afimmune has only $400,000 in revs. losing a bunch of money so why not!
Mass, Amarin is aware of epeleuton via their connection with Bhatt. I think it would be fabulous if Amarin partnered/invested in Afimmune. Perhaps premature wishing as it will take years for anything to materialize as a marketable product. Screw the generics!
ILT, Please see below a copy of Elisabeth's response to my questions asking about any affiliation between Afimmune and Amarin.
Hi - We have discussed Epeleuton with Dr. Bhatt.
I don’t have any information to offer though on the stories you are mentioning as this is not our drug nor our trials.
Thank you,
Elisabeth
Elisabeth Schwartz, Sr. Director of Investor Relations, Amarin Corporation plc
440 Route 22, Bridgewater, NJ 08807
Direct Number 908.326.2569
Email: elisabeth.schwartz@amarincorp.com
ILT, before I read your post I sent an email to Elisabeth asking her to explain the current financial relationship between Afimmune and Amarin. Hopefully, there's no conflict of interest and lack of disclosure between the 2 companies. Your post explains several possibilities that could unfold.
ILT, awesome timeline ref the Flynn saga. Disgraceful actions by FBI/Obama/Biden WH.
Thank you.
sts, not sure about stale data but the article was dated 8/4/20. I have more questions now than ever since I found that website but it's cost-prohibitive to subscribe. After I posted that link someone provided a similar link that was free but I couldn't glean any additional info referencing the 8/4 patent info.